Menu Search
Equities

Beijing Tiantan Biological Products Corp Ltd

600161:SHH

Beijing Tiantan Biological Products Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)21.03
  • Today's Change0.13 / 0.62%
  • Shares traded27.42m
  • 1 Year change+0.94%
  • Beta0.8569
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform8
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 4 analysts offering 12 month price targets for Beijing Tiantan Biological Products Corp have a median target of 29.97, with a high estimate of 31.67 and a low estimate of 26.42. The median estimate represents a 43.40% increase from the last price of 20.90.
High51.5%31.67
Med43.4%29.97
Low26.4%26.42

Dividends

In 2023, Beijing Tiantan Biological Products Corp Ltd reported a dividend of 0.13 CNY, which represents a 199.98% increase over last year. The 5 analysts covering the company expect dividends of 0.12 CNY for the upcoming fiscal year, a decrease of 4.80%.
Div growth (TTM)199.98%
More ▼

Earnings history & estimates in CNY

On Jul 12, 2024, Beijing Tiantan Biological Products Corp reported 2nd quarter 2024 earnings of 0.212 per share.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate+30.26%
Beijing Tiantan Biological Products Corp reported annual 2023 earnings of 0.558 per share on Jan 10, 2024.
Average growth rate+13.61%
More ▼

Revenue history & estimates in CNY

of 1.33bn.
Average growth rate+9.51%
Beijing Tiantan Biological Products Co., Ltd. had revenues for the full year 2023 of 5.18bn. This was 21.57% above the prior year's results.
Average growth rate+12.38%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.